Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma

Fineline Cube Feb 4, 2024

Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...

Company

Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels

Fineline Cube Feb 4, 2024

Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...

Company Drug

Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products

Fineline Cube Feb 4, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...

Company Deals

Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion

Fineline Cube Feb 2, 2024

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S....

Company Drug

Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients

Fineline Cube Feb 2, 2024

Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...

Company Deals

Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development

Fineline Cube Feb 2, 2024

Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...

Company

Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal

Fineline Cube Feb 2, 2024

Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma

Fineline Cube Feb 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company

Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales

Fineline Cube Feb 2, 2024

Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...

Company

Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...

Company Drug

Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts

Fineline Cube Feb 2, 2024

Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...

Company

Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand

Fineline Cube Feb 2, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...

Company Deals

Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...

Policy / Regulatory

NHSA Launches Service Specifications for Medical Procurement Platform

Fineline Cube Feb 2, 2024

The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement...

Policy / Regulatory

China’s NHC Unveils 2024 Goals for Medical Quality and Safety Improvement

Fineline Cube Feb 2, 2024

The National Health Commission (NHC) has released the “2024 National Medical Quality and Safety Improvement...

Company

WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility

Fineline Cube Feb 1, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Deals

HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development

Fineline Cube Feb 1, 2024

HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...

Company Deals

Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...

Company Deals

Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally

Fineline Cube Feb 1, 2024

Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...

Company

Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain

Fineline Cube Feb 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...

Posts pagination

1 … 396 397 398 … 657

Recent updates

  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.